Drug manufacturer Bristol Myers Squibb (BMS) yesterday updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos, a potential blockbuster product.
Camzyos is a first-in-class treatment for symptomatic obstructive
…